IonDX Inc., has focused on characterizing various classes of biotherapeutics. Our technology is used to investigate the higher order structure of proteins and other classes of macromolecules. The majority of higher order structural analytics rely on indirect biophysical techniques because x-ray crystallography is not easily implemented in biotherapeutic workflows and many other biologically manufactured products have never been crystallized.
A well-recognized technical challenge is to screen and fingerprint macromolecular structures more rapidly. IonDX’s System utilizes atmospheric pressure ion mobility spectrometry (IMS) to address this concern.
This versatile system can simultaneously measure five important attributes of protein-based drugs: drug concentration, purity, stability, structural conformation and variation. The fast (5-10mins) analysis time and small footprint of our bench-top technology allows it to be utilized routinely throughout all stages of bioprocessing, including process monitoring. IonDX's system, being amenable to automation, will fit into typical biotherapeutic high-throughput workflows, thus reducing time and effort to bring it to market.
The targeted commercial launch of the IonDX system is set for September 2021. Until then, the IonDX team is actively engaging scientists across the biopharma industry. The company is also planning on manufacturing pre-launch systems available for purchase prior to the official release.
To discuss the system, technology or evaluate a prototype, please contact email@example.com